Department of Medicine, University of California San Diego School of Medicine, La Jolla, CA.
Division of STD Prevention, US Centers for Disease Control and Prevention (CDC), Atlanta, GA.
Sex Transm Dis. 2019 Mar;46(3):e18-e25. doi: 10.1097/OLQ.0000000000000929.
The goal of the Sexually Transmitted Infection Clinical Trial Group's Antimicrobial Resistance (AMR) in Neisseria gonorrhoeae (NG) meeting was to assemble experts from academia, government, nonprofit and industry to discuss the current state of research, gaps and challenges in research and technology and priorities and new directions to address the continued emergence of multidrug-resistant NG infections. Topics discussed at the meeting, which will be the focus of this article, include AMR NG global surveillance initiatives, the use of whole genome sequencing and bioinformatics to understand mutations associated with AMR, mechanisms of AMR, and novel antibiotics, vaccines and other methods to treat AMR NG. Key points highlighted during the meeting include: (i) US and International surveillance programs to understand AMR in NG; (ii) the US National Strategy for combating antimicrobial-resistant bacteria; (iii) surveillance needs, challenges, and novel technologies; (iv) plasmid-mediated and chromosomally mediated mechanisms of AMR in NG; (v) novel therapeutic (eg, sialic acid analogs, factor H [FH]/Fc fusion molecule, monoclonal antibodies, topoisomerase inhibitors, fluoroketolides, LpxC inhibitors) and preventative (eg, peptide mimic) strategies to combat infection. The way forward will require renewed political will, new funding initiatives, and collaborations across academic and commercial research and public health programs.
性传播感染临床试验组抗菌药物耐药性（AMR）会议的目标是召集来自学术界、政府、非营利组织和行业的专家，讨论当前研究的状况、研究和技术方面的差距和挑战，以及解决耐多药淋病奈瑟菌感染持续出现的优先事项和新方向。会议讨论的主题将是本文的重点，包括 AMR 淋病奈瑟菌的全球监测计划、使用全基因组测序和生物信息学来了解与 AMR 相关的突变、AMR 的机制，以及新型抗生素、疫苗和其他治疗耐多药淋病奈瑟菌的方法。会议期间强调的要点包括：（i）了解淋病奈瑟菌 AMR 的美国和国际监测计划；（ii）美国对抗抗菌药物耐药菌的国家战略；（iii）监测需求、挑战和新技术；（iv）淋病奈瑟菌中质粒介导和染色体介导的 AMR 机制；（v）新型治疗（例如唾液酸类似物、补体因子 H [FH]/Fc 融合分子、单克隆抗体、拓扑异构酶抑制剂、氟喹诺酮类、LpxC 抑制剂）和预防（例如肽模拟）策略来对抗感染。前进的道路将需要重新激发政治意愿、新的资助倡议，以及学术界、商业研究和公共卫生计划之间的合作。
